DexCom, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jacob Steven Leach
- Full Time Employees
- 10,200
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 6340 Sequence Drive San Diego CA United States of America 92121
- IPO Date
- Apr 14, 2005
- CIK
- 0001093557
- Website
- dexcom.com
- Similar Companies
- Business
- DexCom, Inc. is a leading medical technology firm dedicated to the engineering, production, and worldwide distribution of continuous glucose monitoring (CGM) solutions. The company's innovative systems are utilized by individuals managing diabetes, as well as by healthcare professionals, to facilitate enhanced glucose management. Its portfolio includes the sophisticated Dexcom G7 system, noted for its compact design, rapid warm-up, and all-in-one sensor with integrated transmitter, which stands as the most accurate CGM available and offers direct connectivity to smartwatches. Dexcom also provides the reliable Dexcom G6, an integrated CGM system, and the simplified Dexcom ONE, aimed at replacing routine fingerstick blood glucose testing for treatment decisions. Expanding its reach, Dexcom launched the Stelo Glucose Biosensor System in 2024, offering an over-the-counter CGM option for adults not on insulin, focusing on metabolic health and lifestyle insights. The company further empowers users with Dexcom Share, a remote monitoring feature, and the Dexcom Real-Time API, enabling third-party developers to integrate live CGM data into various digital health applications. Additionally, Dexcom Clarity provides a cloud-based platform for glucose trend analysis and reporting for both users and healthcare providers. In recent developments, Dexcom received FDA clearance in November 2025 for Dexcom Smart Basal, the first CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes on glargine U-100 long-acting insulin, slated for a December 2025 launch alongside an extended 15-day G7 sensor. Dexcom actively pursues partnerships, including collaborations with insulin pump manufacturers and digital health platforms to expand system compatibility. Founded in 1999, DexCom, Inc. is headquartered in San Diego, California, and maintains a global presence.
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
DexCom: The Growth Thesis Still Needs To Be Proven
Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now?
DexCom to Roll Out Reimagined Stelo App With Global Expansion Plans
Dexcom Further Advances Vision of Glucose Biosensing for All
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
Living Longer Is Big Business. These Stocks Will Benefit.
3 Stocks Doing the Heavy Lifting in Healthcare's Rebound
The Healthcare M&A Wave
DXCM Receives FDA Clearance for Stelo OTC CGM System for Children
Here's Why DexCom (DXCM) is a Strong Growth Stock
FDA clears first over-the-counter glucose monitor for children
Pharmsource says it was unaware Dexcom sensors it bought were slated for destruction
Why DexCom (DXCM) is a Top Momentum Stock for the Long-Term
DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes
Clinical Wins Boost Dexcom Growth Story In Type 2 Diabetes
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
Here's Why You Should Retain DexCom Stock in Your Portfolio